Skip to main content

Clinical trial BOT112-02

Phase IIa open-label clinical study of intratumoural administration of BO-112 in combination with pembrolizumab in subjects with liver metastasis from colorectal cancer or gastric/gastro-oesophageal junction cancer

Cancers
Organ Multiple
Trial status Trial closed
Investigator
Trial type
Interventional with experimental drug
Phase Trial phase 2
Academic trial Non
Sponsor Highlight Therapeutics S.L.
EudraCT Identifier 2019-004624-38
ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT04508140
Inclusion criteria unresectable liver metastases
Last update